Moscow, 05 December, 2007 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announces its unreviewed and unaudited sales results for the nine months ended 30 September 2007.

Company revenue achieved RUR7,755 million (US$299.7^[1] million) in 9 months 2007 and grew by 53% from RUR5,077 million (US$185.5 million) in 9 months 2006. On pro-forma^[2] basis revenue growth reached 31% from RUR5,928 million (US$216.6 million) in 9 months 2006 to RUR7,755 million (US$299.7 million) in 9 months 2007.

In third quarter 2007 Pharmstandard launched two new OTC products Complivit 365® and Complivit Calcium D3®.

According to Pharmexpert 9 month 2007 data Pharmstandard was the leader on the commercial sector of Russian pharmaceutical market and demonstrated 29% growth rate from 3.99% market share in 9 months 2006 to 4.35% market share in 9 month 2007. Arbidol® and Pentalgin® were rated within TOP-10 market leading brands on the commercial segment of the market among all brands. Arbidol® rated as #1 at commercial segment and demonstrated 49% growth rate from 0.91% market share in 9 months 2006 to 1.15% market share in 9 months 2007. Pentalgin® changed rank from 13th position to 7th and demonstrated 51% growth from 0.51% market share in 9 months 2006 to 0.66% market share in 9 months 2007.

On 4th of December OJSC Pharmstandard received Annual National Business Award “The Company of the Year 2007” in the sector of pharmaceutical industry.

^[1] All USD figures based on average exchange rates for the relevant periods. These were USD/RUR 27.37 for 9 months 2006 and USD/RUR 25.88 for 9 months 2007.
^[2] Pro Forma assumes inclusion of Masterlek as part of Pharmstandard as of 1 January 2006.